Financial Highlights and Corporate Update
Zealand Pharma A/S (NASDAQ: ZEAL) has announced impressive financial results for the first nine months of the year. The company's commitment to innovation in peptide-based medicines is at the forefront, and as they approach pivotal clinical data releases, excitement for the future is palpable.
Key Milestones Achieved
One of the notable achievements includes successfully reaching a significant milestone in the petrelintide Phase 2 ZUPREME-1 trial, where the last participant recently completed an important 28-week visit. This pivotal moment sets the stage for anticipated topline data in the first half of 2026.
Advancements in Survodutide
In addition to the progress with petrelintide, Zealand Pharma is also gearing up for data in the Phase 3 trials of survodutide. The last participant has completed the 76-week SYNCHRONIZE-1 trial, which is focused on individuals with overweight and obesity, excluding type 2 diabetes. This data is expected to emerge around the same time as the data from petrelintide.
Strategic Directions for 2026
Looking forward, Zealand Pharma's upcoming Capital Markets Day is scheduled for December 11, where the company aims to outline its strategy for 2026 and emphasize its plans to drive further innovation in treating obesity. This event is poised to be a turning point as Zealand aims to establish itself as a leading biotech company.
CEO's Insights
Adam Steensberg, President and CEO of Zealand Pharma, expressed his optimism regarding the strong momentum in their clinical programs, alongside a fruitful partnership with Roche. He indicated readiness to share exciting developments at the upcoming Capital Markets Day, where the ambitious research strategies aimed at obesity will be detailed.
Financial Performance Overview
The financial performance for the third quarter indicates a revenue of DKK 9,146 million, a significant increase compared to DKK 54 million in the same period last year. However, net operating expenses were recorded at DKK 1,479 million.
Cash Position and Future Guidance
As of September 30, 2025, Zealand maintains a robust cash position of DKK 16,169 million, up from DKK 9,022 million at the end of 2024. The updated financial guidance indicates a narrowing of expected net operating expenses, now projected between DKK 2.0-2.3 billion, reflecting strategic prioritization in their development portfolio.
Clinical Development Pipeline
Zealand continues to advance its pipeline with several significant trials. The petrelintide program is ongoing, and the company expects to report topline results from the 42-week Phase 2 ZUPREME-1 trial early in 2026. Additionally, the Phase 2 ZUPREME-2 trial is expected to yield topline results later in 2026, further solidifying Zealand's position in the obesity treatment space.
Upcoming Trials and Partnerships
Zealand Pharma is also planning to test the fixed-dose combination of petrelintide and CT-388 in a Phase 2 study set for the first half of 2026. Moreover, the company has made a pivotal decision to pause the development of dapiglutide, redirecting resources towards the most promising programs that showcase potential clinical differentiation.
Company Background and Future Aspirations
Founded in 1998 and headquartered in Copenhagen, Zealand Pharma has cultivated a portfolio of innovative therapies aimed at obesity and rare diseases. With a strong focus on research and strategic partnerships, Zealand is positioned to lead advancements in peptide-based medicines. More than ten of its drug candidates have entered clinical stages, reaffirming the company's commitment to changing the landscape of treatment for patients.
Contact Information for Investors
For inquiries, investors may contact:
- Adam Lange, Vice President, Investor Relations, Zealand Pharma, Email: ALange@zealandpharma.com
- Neshat Ahmadi, Investor Relations Manager, Zealand Pharma, Email: NeAhmadi@zealandpharma.com
- Rachel James-Owens, Vice President, Corporate Communications & Media Relations, Zealand Pharma, Email: RJamesOwens@zealandpharma.com
Frequently Asked Questions
What are the key highlights from Zealand Pharma's financial results?
Zealand Pharma reported revenues of DKK 9,146 million in the third quarter, with increased cash position and narrowed financial guidance for net operating expenses.
When will Zealand Pharma release data from its key trials?
The company expects topline results from its petrelintide and survodutide trials in the first half of 2026.
What is Zealand Pharma's strategy for 2026?
Zealand aims to showcase its commitments to innovation in obesity treatments through strategic updates at its Capital Markets Day in December.
Is there any important information regarding partnerships?
Zealand has developed significant partnerships, particularly with Roche, enhancing its clinical pipeline and development strategies.
Who can I contact for investor inquiries?
For investor relations, reach out to Adam Lange, Neshat Ahmadi, or Rachel James-Owens via their provided emails.
